Document 0213
 DOCN  M9550213
 TI    Antiretroviral therapy for children.
 DT    9505
 AU    Krasinski K; Department of Pediatrics, New York University Medical
       Center, New; York.
 SO    Acta Paediatr Suppl. 1994 Aug;400:63-9. Unique Identifier : AIDSLINE
       MED/95135023
 AB    Advances in the development of antiviral drugs have been rapid and
       dramatic. Since the recognition of HIV-1 as the cause of AIDS in 1984,
       and improved understanding of retroviral replication and pathogenesis,
       three antiviral drugs, Zidovudine, Didanosine, and Zalcitabine, have
       been developed to the point of routine use in humans. There is
       substantial experience with the former two in children. Despite being
       unable to cure HIV-1 infection, the benefits of antiretroviral therapy,
       including extended survival and reductions in opportunistic infections
       in adults, and improved weight gain and well-being in children, are
       strong arguments for routine treatment of symptomatic disease. Because
       these agents may also interfere with human cellular processes and have
       toxicities including anemia, neutropenia, pancreatitis, and neuropathy,
       their routine use for the treatment of asymptomatic children requires
       further controlled study. There are multiple candidate agents being
       developed for entry into clinical trials. An additional potentially
       effective strategy is the use of combinations of drugs at the same time
       or in sequence to maximize the viral targets being attacked, while
       minimizing toxicity, and to prevent the emergence of a drug-resistant
       virus.
 DE    Acquired Immunodeficiency Syndrome/*DRUG THERAPY/IMMUNOLOGY/  VIROLOGY
       Adult  Child  Clinical Trials  Controlled Clinical Trials
       Didanosine/*THERAPEUTIC USE  Drug Resistance, Microbial  DNA,
       Viral/ANALYSIS  Human  HIV-1/*DRUG EFFECTS/GENETICS/PHYSIOLOGY
       Immunity, Cellular  Virus Replication  Zalcitabine/*THERAPEUTIC USE
       Zidovudine/*THERAPEUTIC USE  JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).